Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cancer-cell derived S100A11 promotes macrophage recruitment in ER+ breast cancer.
Lee S, Cho Y, Li Y, Li R, Lau AW, Laird MS, Brown D, McAuliffe P, Lee AV, Oesterreich S, Zervantonakis IK, Osmanbeyoglu HU. Lee S, et al. Among authors: osmanbeyoglu hu. Oncoimmunology. 2024 Dec 31;13(1):2429186. doi: 10.1080/2162402X.2024.2429186. Epub 2024 Nov 26. Oncoimmunology. 2024. PMID: 39587886 Free PMC article.
Low Exposures to Amphibole or Serpentine Asbestos in Germline Bap1-mutant Mice Induce Mesothelioma Characterized by an Immunosuppressive Tumor Microenvironment.
Kadariya Y, Sementino E, Ruan M, Cheung M, Hadikhani P, Osmanbeyoglu HU, Klein-Szanto AJ, Cai K, Testa JR. Kadariya Y, et al. Among authors: osmanbeyoglu hu. Cancer Res Commun. 2024 Apr 8;4(4):1004-1015. doi: 10.1158/2767-9764.CRC-23-0423. Cancer Res Commun. 2024. PMID: 38592450 Free PMC article.
Cancer-cell derived S100A11 promotes macrophage recruitment in ER+ breast cancer.
Lee S, Cho Y, Li Y, Li R, Brown D, McAuliffe P, Lee AV, Oesterreich S, Zervantonakis IK, Osmanbeyoglu HU. Lee S, et al. Among authors: osmanbeyoglu hu. bioRxiv [Preprint]. 2024 Mar 26:2024.03.21.586041. doi: 10.1101/2024.03.21.586041. bioRxiv. 2024. Update in: Oncoimmunology. 2024 Dec 31;13(1):2429186. doi: 10.1080/2162402X.2024.2429186 PMID: 38585952 Free PMC article. Updated. Preprint.
Clinical and biomarker results from a phase II trial of combined cabozantinib and durvalumab in patients with chemotherapy-refractory colorectal cancer (CRC): CAMILLA CRC cohort.
Saeed A, Park R, Pathak H, Al-Bzour AN, Dai J, Phadnis M, Al-Rajabi R, Kasi A, Baranda J, Sun W, Williamson S, Chiu YC, Osmanbeyoglu HU, Madan R, Abushukair H, Mulvaney K, Godwin AK, Saeed A. Saeed A, et al. Among authors: osmanbeyoglu hu. Nat Commun. 2024 Feb 20;15(1):1533. doi: 10.1038/s41467-024-45960-2. Nat Commun. 2024. PMID: 38378868 Free PMC article. Clinical Trial.
41 results